Infinity Pharmaceuticals Inc
OTC:INFIQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Infinity Pharmaceuticals Inc
OTC:INFIQ
|
US |
|
First Brothers Co Ltd
TSE:3454
|
JP |
|
R
|
Rio Tinto PLC
XHAM:RIO1
|
UK |
|
Amana Cooperative Insurance Company SJSC
SAU:8310
|
SA |
|
Jiangsu Chengxing Phosph-Chemical Co Ltd
SSE:600078
|
CN |
|
J
|
J D Wetherspoon PLC
LSE:JDW
|
UK |
|
Red Planet Japan Inc
TSE:3350
|
JP |
|
Jung Shing Wire Co Ltd
TWSE:1617
|
TW |
Infinity Pharmaceuticals Inc
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase 1/1b clinical study.
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase 1/1b clinical study.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
